ReviewCurrent atherosclerosis reports2000
Electron beam tomography as an endpoint for clinical trials of antiatherosclerotic therapy.
Review in Current atherosclerosis reports, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- The Atherosclerosis Risk in Young Adults (ARYA) study: rationale and design.European journal of epidemiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current antiatherosclerotic therapies are highly effective and have induced a factual reduction in morbidity and mortality related to atherosclerotic disease. This makes it difficult for clinical researchers to demonstrate a further reduction in hard events. On the other hand, angiographic studies have conclusively demonstrated that coronary artery disease regression can be used as a valid surrogate endpoint. In fact, small improvements in luminal diameter stenosis corresponded to a substantial reduction in event rates. However, because coronary angiography is invasive and expensive, other surrogate endpoints may be more desirable to ascertain the effectiveness of therapy. With electron beam tomography imaging the coronary artery tree is visualized noninvasively and vascular calcification, a marker of atherosclerotic disease, is easily detected and its extent quantified. Preliminary studies have shown that this technology provides an opportunity to serially monitor the effectiveness of medical therapy for coronary artery disease at low cost and low risk for the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.